Guardant Health (NASDAQ:GH) Director Meghan Joyce Sells 10,000 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Meghan Joyce sold 10,000 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total value of $1,269,800.00. Following the completion of the sale, the director directly owned 11,183 shares of the company’s stock, valued at $1,420,017.34. The trade was a 47.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Price Performance

Guardant Health stock opened at $133.06 on Friday. The stock has a market capitalization of $17.64 billion, a price-to-earnings ratio of -39.25 and a beta of 1.61. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $134.28. The business has a fifty day moving average price of $98.61 and a 200-day moving average price of $100.91.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GH. TD Cowen reissued a “buy” rating on shares of Guardant Health in a research report on Thursday, May 21st. The Goldman Sachs Group set a $165.00 price objective on Guardant Health and gave the stock a “buy” rating in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. BTIG Research set a $160.00 price objective on Guardant Health and gave the stock a “buy” rating in a research report on Wednesday, May 27th. Finally, Stifel Nicolaus raised their price objective on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and a consensus price target of $137.80.

Hedge Funds Weigh In On Guardant Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Allworth Financial LP grew its position in shares of Guardant Health by 19.5% in the third quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after purchasing an additional 138 shares in the last quarter. Eastern Bank grew its position in shares of Guardant Health by 6.9% in the fourth quarter. Eastern Bank now owns 2,160 shares of the company’s stock valued at $221,000 after purchasing an additional 139 shares in the last quarter. First Pacific Financial raised its position in shares of Guardant Health by 33.1% during the 1st quarter. First Pacific Financial now owns 559 shares of the company’s stock valued at $52,000 after buying an additional 139 shares during the period. TD Waterhouse Canada Inc. raised its position in shares of Guardant Health by 3.2% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock valued at $306,000 after buying an additional 151 shares during the period. Finally, Xponance LLC raised its position in shares of Guardant Health by 2.1% during the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after buying an additional 199 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.